Clinical trials: Fatty Acid Oxidation Disorder
Nonalcoholic Steatohepatitis, Liver Fibrosis
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem.
- Trial name
- NCT05526144
- Testing
- Synthroid
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- VA Office of Research and Development
Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2
Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
The purpose of the study is to determine if an oral ketone beverage is safe and well-tolerated during moderate intensity exercise in participants with long-chain fatty acid oxidation disorders and if it will raise blood ketones…
- Conditions
- Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Trifunctional Protein Deficiency
- Trial name
- NCT05411835
- Testing
- Nutritional Ketone Supplement
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or…
- Trial name
- NCT04812106
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Metabolic Syndrome, Obesity
Genistein Stimulates Insulin Sensitivity Through Gut Microbiota
There is evidence that genistein present in soy can improve insulin resistance in rodents and humans with metabolic syndrome (MetS). However, it is not known if this improvement is associated with changes in the gut microbiota.
- Trial name
- GENISTEIN (NCT04105023)
- Testing
- genistein
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Heart Failure
The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure
A diet rich in Omega-3 (fish oil) reduces plasma triglycerides and the risk for ischemic heart disease. Recently, a large trial evaluating treatment with Omega 3 in heart failure patients suggested that omega 3 may lower the risk…
- Trial name
- NCT00944229
- Testing
- LOVAZA (Omega-3)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Columbia University
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy.
- Conditions
- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency
- Trial name
- Triheptanoin (NCT01379625)
- Testing
- Triheptanoin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Oregon Health and Science University
Fatty Acid Oxidation Disorders
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders
The purpose of this Phase 1b study is to assess REN001 safety in subjects with fatty acid oxidation disorders.
- Trial name
- NCT03833128
- Testing
- Low Dose REN001, High Dose REN001
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 24 people
- Sponsor
- Reneo Pharma Ltd
Pulmonary Artery Hypertension
Trimetazidine in Pulmonary Artery Hypertension
Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15 persons per million. Although current therapy has improve disease prognosis, PAH still has a poor survival, with a median survival of 2.8…
- Trial name
- NCT02102672
- Testing
- Trimetazidine
- Where
- Chile
- Volunteers
- 25 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Fatty Acid Oxidation Disorder
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders
The purpose of the study is to collect information on disease characteristics from adult patients diagnosed with fatty acid oxidation disorders (FAOD).
- Trial name
- FORWARD (NCT04482049)
- Where
- 15 sites in United States, Austria and 9 more
- Volunteers
- 61 people
- Sponsor
- Reneo Pharma Ltd
Obesity, Diabetes
Differential Metabolism of Dietary Fatty Acids
Differences in how diet fats are converted to energy could explain some of the reported differences in health effects among different classes of dietary fat (e.g. monounsaturated vs. saturated).
- Conditions
- Obesity, Diabetes, Hyperlipidemia
- Trial name
- NCT00059254
- Testing
- Oleic acid (OA), Palmitic Acid (PA)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Ketosis, Epilepsy
Market Research - Acceptability Study for New MCT Fat Products
This is a market research, observational study to evaluate the tolerability and acceptability of MCT supplements for young children, young people and adults with intractable epilepsy, GLUT-1 or PDHD from 3 years to adulthood.
- Conditions
- Ketosis, Epilepsy, Fatty Acid Oxidation Disorder, Malabsorption
- Trial name
- NCT04309214
- Testing
- MCT fats
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Dr. Schär AG / SPA
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
- Trial name
- NCT03768817
- Testing
- No Intervention
- Where
- 15 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Fatty Acid Oxidation Disorder
Experience of Using Lipano in Children With Fatty Acid Oxidation Disorders
This is a market research, observational study to evaluate the tolerability and acceptability of an MCT based formula for infants and young people with long chain fatty acid oxidation disorder from birth to 18 months.
- Trial name
- NCT04400422
- Testing
- Lipano formula
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Dr. Schär AG / SPA
Carnitine Palmitoyltransferase II Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD)…
- Trial name
- Bezafibrate (NCT00983788)
- Testing
- Bezafibrate
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
- Trial name
- NCT05933200
- Testing
- Triheptanoin, MCT Oil
- Where
- 15 sites in Czechia, Germany and 5 more
- Volunteers
- 69 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Metabolic Syndrome X, Prediabetic State
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
The relationship between obesity and insulin resistance is known, however the mechanism(s) associating obesity with insulin resistance is not well understood.
- Trial name
- NCT00470262
- Testing
- Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency
Fatty Acid Oxidation Defects and Insulin Sensitivity
The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the…
- Conditions
- Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency
- Trial name
- NCT02517307
- Testing
- Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Obesity
Obesity, Physical Inactivity or Dietary Fat ?
Obesity is the consequence of a chronic disequilibrium of fat balance. Genetic factors determine predisposition to obesity, but the most often mentioned idea is that environmental factors, such as a high-fat diet and a sedentary…
- Trial name
- NCT00434265
- Testing
- Physical training
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Strasbourg, France
Mitochondrial Myopathies, Fatty Acid Oxidation Defects
Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders
The purpose of this study is to investigate the potential beneficial effects of a daily supplement of Resveratrol (1000mg/day) on physical ability and on muscle metabolism in patients with verified mitochondrial myopathy and…
- Trial name
- NCT03728777
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency
A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment.
- Conditions
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
- Trial name
- NCT01886378
- Testing
- UX007
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Ultragenyx Pharmaceutical Inc